{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:56:53Z","timestamp":1792522613683,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40266-024-01114-z","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T10:01:54Z","timestamp":1715335314000},"page":"431-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7325-7523","authenticated-orcid":false,"given":"Estelle","family":"Tran Van Hoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Trompet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Van Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederiek","family":"Van Den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Van Heemst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Codrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Labots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanneke","family":"Portielje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Mooijaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke A.","family":"De Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"1114_CR1","unstructured":"NIH-SEER. Cancer of any site. Cancer Stat Facts 2019. https:\/\/seer.cancer.gov\/statfacts. Accessed 8 Jan 2021."},{"issue":"6","key":"1114_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","volume":"26","author":"C Handforth","year":"2015","unstructured":"Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2015;26(6):1091\u2013101.","journal-title":"Ann Oncol"},{"issue":"25","key":"1114_CR3","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457\u201365.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1114_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1634\/theoncologist.2020-0804","volume":"25","author":"E Soto-Perez-de-Celis","year":"2020","unstructured":"Soto-Perez-de-Celis E, Aapro M, Muss H. ASCO 2020: The geriatric asessment comes of age. Oncologist. 2020;25(11):909\u201312.","journal-title":"Oncologist"},{"issue":"10314","key":"1114_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet. 2021;398(10314):1894\u2013904.","journal-title":"Lancet"},{"issue":"11","key":"1114_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4158","volume":"7","author":"D Li","year":"2021","unstructured":"Li D, Sun CL, Kim H, Soto-Perez-de-Celis E, Chung V, Koczywas M, et al. Geriatric Assessment-Driven Intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11): e214158.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1114_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1759-7714.13272","volume":"11","author":"A Ruiz-Patino","year":"2020","unstructured":"Ruiz-Patino A, Arrieta O, Cardona AF, Martin C, Raez LE, Zatarain-Barron ZL, et al. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thorac Cancer. 2020;11(2):353\u201361.","journal-title":"Thorac Cancer."},{"issue":"3","key":"1114_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.21037\/jtd.2020.03.11","volume":"12","author":"B Cheng","year":"2020","unstructured":"Cheng B, Xiong S, Li C, Liang H, Zhao Y, Li J, et al. An annual review of the remarkable advances in lung cancer clinical research in 2019. J Thorac Dis. 2020;12(3):1056\u201369.","journal-title":"J Thorac Dis"},{"key":"1114_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","volume":"17","author":"X Wu","year":"2019","unstructured":"Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661\u201374.","journal-title":"Comput Struct Biotechnol J"},{"key":"1114_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","volume":"82","author":"A Daste","year":"2017","unstructured":"Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, et al. Immune checkpoint inhibitors and elderly people: a review. Eur J Cancer. 2017;82:155\u201366.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1114_CR11","first-page":"219","volume":"23","author":"KA Marrone","year":"2017","unstructured":"Marrone KA, Forde PM. Cancer immunotherapy in older patients. Cancer J. 2017;23(4):219\u201322.","journal-title":"Cancer J"},{"key":"1114_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104259","volume":"194","author":"A Ozkan","year":"2024","unstructured":"Ozkan A, van den Bos F, Mooijaart SP, Slingerland M, Kapiteijn E, de Miranda N, et al. Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: a systematic review. Crit Rev Oncol Hematol. 2024;194: 104259.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"1114_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40266-019-00697-2","volume":"36","author":"Y van Holstein","year":"2019","unstructured":"van Holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging. 2019;36(10):927\u201338.","journal-title":"Drugs Aging"},{"key":"1114_CR14","doi-asserted-by":"crossref","unstructured":"van Holstein Y, van Deudekom FJ, Trompet S, Postmus I, Uit den Boogaard A, van der Elst MJT, et al. Design and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment. BMC Geriatr. 2021;21(1):29.","DOI":"10.1186\/s12877-020-01975-0"},{"issue":"6","key":"1114_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.bpg.2009.10.001","volume":"23","author":"A Pilotto","year":"2009","unstructured":"Pilotto A, Addante F, D\u2019Onofrio G, Sancarlo D, Ferrucci L. The Comprehensive Geriatric Assessment and the multidimensional approach: a new look at the older patient with gastroenterological disorders. Best Pract Res Clin Gastroenterol. 2009;23(6):829\u201337.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"1114_CR16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","volume":"89","author":"SP Blagden","year":"2003","unstructured":"Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89(6):1022\u20137.","journal-title":"Br J Cancer"},{"key":"1114_CR17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 27 Nov 2017."},{"issue":"3","key":"1114_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jgo.2019.05.021","volume":"11","author":"K Welaya","year":"2020","unstructured":"Welaya K, Loh KP, Messing S, Szuba E, Magnuson A, Mohile SG, et al. Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors. J Geriatr Oncol. 2020;11(3):523\u20138.","journal-title":"J Geriatr Oncol."},{"issue":"11","key":"1114_CR19","doi-asserted-by":"publisher","first-page":"8993","DOI":"10.1007\/s00432-023-04792-1","volume":"149","author":"J Gao","year":"2023","unstructured":"Gao J, Zhang P, Tang M, Nie X, Yuan Y, Yang F, et al. Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer: a prospective real-world analysis. J Cancer Res Clin Oncol. 2023;149(11):8993\u20139006.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"1114_CR20","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1002\/cncr.34230","volume":"128","author":"CP Bruijnen","year":"2022","unstructured":"Bruijnen CP, Koldenhof JJ, Verheijden RJ, van den Bos F, Emmelot-Vonk MH, Witteveen PO, et al. Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer. 2022;128(14):2746\u201352.","journal-title":"Cancer"},{"issue":"1","key":"1114_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100042","volume":"6","author":"F Gomes","year":"2021","unstructured":"Gomes F, Lorigan P, Woolley S, Foden P, Burns K, Yorke J, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients: the ELDERS study. ESMO Open. 2021;6(1): 100042.","journal-title":"ESMO Open."},{"issue":"7","key":"1114_CR22","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00262-023-03371-0","volume":"72","author":"AC Johns","year":"2023","unstructured":"Johns AC, Yang M, Wei L, Grogan M, Patel SH, Li M, et al. Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy. Cancer Immunol Immunother. 2023;72(7):2005\u201313.","journal-title":"Cancer Immunol Immunother"},{"key":"1114_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejca.2019.08.027","volume":"121","author":"P Corbaux","year":"2019","unstructured":"Corbaux P, Maillet D, Boespflug A, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur J Cancer. 2019;121:192\u2013201.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1114_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-016-0534-9","volume":"18","author":"R Elias","year":"2016","unstructured":"Elias R, Morales J, Rehman Y, Khurshid H. Immune checkpoint inhibitors in older adults. Curr Oncol Rep. 2016;18(8):47.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"1114_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jgo.2017.02.001","volume":"8","author":"R Elias","year":"2017","unstructured":"Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017;8(3):229\u201335.","journal-title":"J Geriatr Oncol."},{"issue":"5","key":"1114_CR26","doi-asserted-by":"publisher","first-page":"djv366","DOI":"10.1093\/jnci\/djv366","volume":"108","author":"NA de Glas","year":"2016","unstructured":"de Glas NA, Kiderlen M, Vandenbroucke JP, de Craen AJ, Portielje JE, van de Velde CJ, et al. Performing survival analyses in the presence of competing risks: a clinical example in older breast cancer patients. J Natl Cancer Inst. 2016;108(5):djv366.","journal-title":"J Natl Cancer Inst"},{"issue":"29","key":"1114_CR27","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1200\/JCO.2013.49.6125","volume":"31","author":"H Wildiers","year":"2013","unstructured":"Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer\u2013Alliance for Clinical Trials in Oncology-International Society Of Geriatric Oncology position article. J Clin Oncol. 2013;31(29):3711\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1114_CR28","first-page":"211","volume":"23","author":"G Nightingale","year":"2017","unstructured":"Nightingale G, Skonecki E, Boparai MK. The impact of polypharmacy on patient outcomes in older adults with cancer. Cancer J. 2017;23(4):211\u20138.","journal-title":"Cancer J"},{"issue":"9","key":"1114_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40266-023-01048-y","volume":"40","author":"M Perret","year":"2023","unstructured":"Perret M, Bertaut A, Niogret J, Marilier S, Jouanny P, Manckoundia P, et al. Associated factors to efficacy and tolerance of immunotherapy in older patients with cancer aged 70 years and over: impact of coprescriptions. Drugs Aging. 2023;40(9):837\u201346.","journal-title":"Drugs Aging"},{"issue":"10","key":"1114_CR30","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00432-020-03252-4","volume":"146","author":"T Hakozaki","year":"2020","unstructured":"Hakozaki T, Hosomi Y, Shimizu A, Kitadai R, Mirokuji K, Okuma Y. Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1\/PD-L1 antibody-based immunotherapy. J Cancer Res Clin Oncol. 2020;146(10):2659\u201368.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"1114_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jgo.2020.03.001","volume":"11","author":"G Lu-Yao","year":"2020","unstructured":"Lu-Yao G, Nightingale G, Nikita N, Keith S, Gandhi K, Swartz K, et al. Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy. J Geriatr Oncol. 2020;11(4):579\u201385.","journal-title":"J Geriatr Oncol."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01114-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01114-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T13:03:01Z","timestamp":1715691781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01114-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01114-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"19 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Estelle Tran Van Hoi, Johanneke Portielje, Diana van Heemst, Nienke De Glas, Simon Mooijaart, and Marloes Derks have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}},{"value":"Ethical approval and consent to participate in the TENT and IMAGINE study protocols was approved by the Medical Ethics Committee at Leiden University Medical Center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants or a proxy provided written informed consent. The Medical Ethics Committee at Southwest Holland issued that ImToSa was not subject to a Medical Research Involving Human Subjects Act (WMO) declaration. Patients consent was therefore not requested.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ST, YVH, and FVDB contributed to the design and implementation of the TENT study. HC and GL contributed to the implementation of ImToSa. AO contributed to the patients follow-up and managed the IMAGINE study database. SL contributed to preparing the database of the present study. ETVH carried out the research and analysis with the supervision of NADG, JP, SPM, and MD. MD conducted the present research.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}